Monoclonal antibodies are playing a key therapeutic role in the treatment of some Covid-19 patients, but new research suggests that nanobodies derived from llamas could provide an alternative to monoclonal antibodies through a more effective delivery method—inhalation.
French researchers are using tiny antibody particles extracted from the family of animals that includes camels and llamas to produce a test they say can detect if patients have Covid-19 faster and more accurately than existing methods.
Nanobodies derived from llamas have neutralized the SARS-CoV-2 spike in the lab, effectively neutralizing the virus, according to research from the UK’s Rosalind Franklin Institute.
Scientists in Sweden are hoping an alpaca named Tyson can help deliver a knockout blow in the fight to develop a treatment or vaccine against the novel coronavirus.
The U.S. FDA approved Cablivi in combination with plasma exchange and immunosuppression for treating acquired thrombotic thrombocytopenic purpura (aTTP) in adults.
The French drugmaker Sanofi secured approval in Europe for a rare blood-clotting disorder treatment using nanobodies.
Sanofi Genzyme, the French company’s rare-disease division based in Cambridge, Mass., announced it is laying off 130 people at a manufacturing facility in Boston.
One week after Sanofi agreed to buy Waltham, Mass.-based Bioverativ for $11.6 billion, the French drugmaker announced the acquisition of Ghent, Belgium-based Ablynx for about $4.85 billion.
French drugmaker Sanofi boosted its early-stage pipeline in immunology by signing a deal with Ablynx that could earn the Belgian biotech firm as much as 2.4 billion euros ($2.8 billion).
